North America Telmisartan Market By Indication (Hypertension and Cardiovascular Risk Reduction), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies), By Country, Growth Potential, Industry Analysis Report and Forecast, 2020 - 2026

The North America Telmisartan Market is expected to witness market growth of 5.2% CAGR during the forecast period (2020-2026).

Accessibility of superior treatment alternatives for hypertension has led considerable part of the hypertensive population with regulated blood pressure. The increasing population with cardiovascular & related disorders encourages the requirement for various antihypertensive drugs in the global market. Telmisartan is considered a non-peptide angiotensin receptor blocker that is aimed at the treatment of hypertension and other cardiovascular disorders. Telmisartan received approval from the US Food and Drug Administration (USFDA) in 1998, with an aim to treat hypertension alone or combined with other elements. This is a serious indication of how more people, each year, are vulnerable to this lifestyle disease. This, in turn, creates growth possibilities for drugs for the treatment of hypertension, and one of the key brands in the market is Telmisartan.

Some of the factors that are responsible for the growth of the Telmisartan market including rising cases of high blood pressure (hypertension), increasing geriatric population, and a surge in supportive government initiatives for increasing awareness about blood pressure diseases. Moreover, the telmisartan market is expected to be supplemented by various factors such as increasing marketing approvals for generic forms of telmisartan, rising sedentary lifestyle, and rising occurrences of chronic diseases like kidney and diabetes. Though, the growth of the telmisartan market is expected to suffer a decline due to the shortages of drugs. On the other hand, increasing investment in R&D activities towards telmisartan drugs in developing countries is expected to present bright prospects during the forecast period.

The US market dominated the North America Cardiovascular Risk Reduction Market by Country in 2019, thereby, achieving a market value of $151.3 million by 2026. The Canada market is experiencing a CAGR of 8.7% during (2020 - 2026). Additionally, The Mexico market is expected to witness a CAGR of 7.8% during (2020 - 2026).

Based on Indication, the market is segmented into Hypertension and Cardiovascular Risk Reduction. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).

Scope of the Study

Market Segments covered in the Report:

By Indication

• Hypertension
• Cardiovascular Risk Reduction

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Country

• US
• Canada
• Mexico
• Rest of North America

Companies Profiled

• Abbott Laboratories
• Aurobindo Pharma Limited
• Boehringer Ingelheim International GmbH
• Cipla Limited
• GlaxoSmithKline PLC (GSK)
• Mylan N.V.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• Cadila Healthcare Ltd. (Zydus Cadila)

Unique Offerings from the Publisher

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free